- Lobbying
- Lobbying by Pharma & Biopharma Outsourcing Association
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Brent Del Monte | Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee See prior filing |
Dave Boyer | Sp Ast Pres LA; Ast Com Leg, FDA; Sp Ast Sec HHS; Con Asst, Off of WH; Liaison DoD Con Asst, Off of Sec Lab See prior filing |
Ryan Long | Prof. Stf, Csel, & Chief Csel H E&C Cmte, LC Rep Norwood; LA& LD Rep Barton See prior filing |
Robb Walton | Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Healthcare Aide Sen. Enzi See prior filing |
John Stone | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel,House E&C Ctme Health Subcommittee See prior filing Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C |
Matthew Hoffmann | St. Asst. Rep. Vitter; LC Rep. Vitter; Sen. LC .Rep. Vitter; LA Rep. Paul Ryan; Sen. LA Rep. Paul Ryan; LD Rep. Paul Ryan; Budget Analyst Rep. Paul Ryan; St. Dir. Health Subcmte House W&M Cmte; Policy Analyst Off. Speaker; Policy Dir. Sen. Fin Cmte. See prior filing |
Remy Brim | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren See prior filing Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz |
Daniel Farmer | St. Asst Rep. Debbie Wasserman Schultz; Leg. Corr. Rep. Debbie Wasserman Schultz; Leg. Corr./Leg. Asst. Rep. Debbie Wasserman Schultz; Leg. Asst. Rep. Zack Space; Sr. Leg. Asst. Rep. Zack Space; Leg. Dir. Zack Space |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Health & Human Services - Dept of (HHS)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Providing advice, counsel, and services to support the PBOAs public policy priorities, which includes the reauthorization of the Generic Drug User Fee Act..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate